Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats.

ABSTRACT: Atherosclerosis is the main cause of cardiovascular diseases which in turn, lead to the highest number of mortalities globally. This pathophysiological condition is developed due to a constant elevated level of plasma cholesterols. Statin is currently the widely used treatment in reducing the level of cholesterols, however, it may cause adverse side effects. Therefore, there is an urgent need to search for new alternative treatment. PCSK9 is an enzyme responsible in directing LDL-receptor (LDL-R)/LDL-cholesterols (LDL-C) complex to lysosomal degradation, preventing the receptor from recycling back to the surface of liver cells. Therefore, PCSK9 offers a potential target to search for small molecule inhibitors which inhibit the function of this enzyme. In this study, a marine invertebrate A

SUBMITTER: Kamaruddin NN 

PROVIDER: S-EPMC8398678 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature